TXB2 and urinary PGIM and TXM values before (visit 2) and after (visit 3) the randomized aspirin regimen in 243 evaluable patients with ET
| . | 100 mg, once daily (n = 85) . | 100 mg twice daily(n = 79) . | 100 mg thrice daily (n = 79) . | Global P* . | P† . |
|---|---|---|---|---|---|
| sTXB2 at V2 (ng/mL) | 17 (8.2-33) | 20 (11.6-6.4) | 23.3 (9.6-46.4) | .098 | .41 |
| sTXB2 at V3 (ng/mL) | 19.3 (9.7-40) | 4 (2.1-6.7) | 2.5 (1.4-5.7) | <.001 | .04 |
| sTXB2 V3/V2 ratio | 1 (0.77-1.5) | 0.1 (0.08-0.3) | 0.1 (0.08-0.2) | <.001 | .24 |
| PGIM at V2 (pg/mg creatinine) | 84 (50-123) | 76 (47-132) | 83 (53-123) | .96 | .74 |
| PGIM at V3 (pg/mg creatinine) | 89 (54-127) | 87 (46-121) | 80 (47-131) | .70 | .90 |
| PGIM V3/V2 ratio | 1.1 (0.7-1.5) | 0.9 (0.7-1.4) | 0.9 (0.6-1.6) | .48 | .88 |
| TXM at V2 (pg/mg creatinine) | 485 (336-693) | 641 (437-864) | 515 (379-738) | .02 | .09 |
| TXM at V3 (pg/mg creatinine) | 457 (313-674) | 367 (237-541) | 344 (229-487) | .001 | .37 |
| TXM V3/V2 ratio | 0.9 (0.7-1.3) | 0.7 (0.5-0.8) | 0.7 (0.5-0.8) | <.001 | .71 |
| . | 100 mg, once daily (n = 85) . | 100 mg twice daily(n = 79) . | 100 mg thrice daily (n = 79) . | Global P* . | P† . |
|---|---|---|---|---|---|
| sTXB2 at V2 (ng/mL) | 17 (8.2-33) | 20 (11.6-6.4) | 23.3 (9.6-46.4) | .098 | .41 |
| sTXB2 at V3 (ng/mL) | 19.3 (9.7-40) | 4 (2.1-6.7) | 2.5 (1.4-5.7) | <.001 | .04 |
| sTXB2 V3/V2 ratio | 1 (0.77-1.5) | 0.1 (0.08-0.3) | 0.1 (0.08-0.2) | <.001 | .24 |
| PGIM at V2 (pg/mg creatinine) | 84 (50-123) | 76 (47-132) | 83 (53-123) | .96 | .74 |
| PGIM at V3 (pg/mg creatinine) | 89 (54-127) | 87 (46-121) | 80 (47-131) | .70 | .90 |
| PGIM V3/V2 ratio | 1.1 (0.7-1.5) | 0.9 (0.7-1.4) | 0.9 (0.6-1.6) | .48 | .88 |
| TXM at V2 (pg/mg creatinine) | 485 (336-693) | 641 (437-864) | 515 (379-738) | .02 | .09 |
| TXM at V3 (pg/mg creatinine) | 457 (313-674) | 367 (237-541) | 344 (229-487) | .001 | .37 |
| TXM V3/V2 ratio | 0.9 (0.7-1.3) | 0.7 (0.5-0.8) | 0.7 (0.5-0.8) | <.001 | .71 |